

Florian Bassermann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9305156/publications.pdf>

Version: 2024-02-01

55
papers

2,205
citations

394421

19
h-index

233421

45
g-index

57
all docs

57
docs citations

57
times ranked

4831
citing authors

#	ARTICLE	IF	CITATIONS
1	The target landscape of clinical kinase drugs. <i>Science</i> , 2017, 358, .	12.6	609
2	The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint. <i>Cell</i> , 2008, 134, 256-267.	28.9	365
3	The ubiquitin proteasome system â€” Implications for cell cycle control and the targeted treatment of cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 150-162.	4.1	214
4	Immunomodulatory drugs disrupt the cereblonâ€”CD147â€”MCT1 axis to exert antitumor activity and teratogenicity. <i>Nature Medicine</i> , 2016, 22, 735-743.	30.7	145
5	RIG-I activation is critical for responsiveness to checkpoint blockade. <i>Science Immunology</i> , 2019, 4, .	11.9	80
6	SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. <i>Nature Cell Biology</i> , 2013, 15, 72-81.	10.3	76
7	CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. <i>Blood</i> , 2021, 138, 1727-1732.	1.4	58
8	Disruption of the PRKCDâ€”FBXO25â€”HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. <i>Nature Medicine</i> , 2014, 20, 1401-1409.	30.7	50
9	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive Bâ€”cell lymphoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 851-862.	6.9	50
10	Î±-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. <i>Oncotarget</i> , 2015, 6, 4692-4703.	1.8	42
11	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. <i>Haematologica</i> , 2020, 105, 2872-2878.	3.5	40
12	The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. <i>Molecular Cell</i> , 2021, 81, 1170-1186.e10.	9.7	39
13	Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. <i>Experimental Hematology and Oncology</i> , 2019, 8, 9.	5.0	36
14	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1765-1771.	5.0	34
15	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. <i>Nature Communications</i> , 2020, 11, 4527.	12.8	32
16	Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis. <i>Blood Advances</i> , 2018, 2, 3447-3461.	5.2	31
17	BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues. <i>Gastroenterology</i> , 2016, 150, 499-512.e20.	1.3	30
18	Multisite Phosphorylation of Nuclear Interaction Partner of ALK (NIPA) at G2/M Involves Cyclin B1/Cdk1. <i>Journal of Biological Chemistry</i> , 2007, 282, 15965-15972.	3.4	28

#	ARTICLE	IF	CITATIONS
19	Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641618.	3.7	25
20	Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. <i>Oncology Research and Treatment</i> , 2021, 44, 672-681.	1.2	25
21	Antagonistic activities of CDC14B and CDK1 on USP9X regulate WT1-dependent mitotic transcription and survival. <i>Nature Communications</i> , 2020, 11, 1268.	12.8	22
22	Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression. <i>Scientific Reports</i> , 2021, 11, 5944.	3.3	20
23	<scp>FBXL</scp> 13 directs the proteolysis of <scp>CEP</scp> 192 to regulate centrosome homeostasis and cell migration. <i>EMBO Reports</i> , 2018, 19, .	4.5	18
24	Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma. <i>Nature Communications</i> , 2022, 13, 281.	12.8	18
25	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. <i>International Review of Cell and Molecular Biology</i> , 2019, 343, 219-297.	3.2	16
26	A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. <i>Bioorganic Chemistry</i> , 2022, 119, 105505.	4.1	13
27	Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells. <i>Scientific Reports</i> , 2019, 9, 14955.	3.3	9
28	Prognostic value of indoleamine 2,3 dioxygenase in patients with higher risk myelodysplastic syndromes treated with azacytidine. <i>British Journal of Haematology</i> , 2020, 190, 361-370.	2.5	9
29	MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF. <i>Cell Death and Differentiation</i> , 2021, 28, 3235-3250.	11.2	9
30	Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8511-8511.	1.6	9
31	Autophagy in mesenchymal progenitors protects mice against bone marrow failure after severe intermittent stress. <i>Blood</i> , 2022, 139, 690-703.	1.4	8
32	Tumor cell intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice. <i>European Journal of Immunology</i> , 2021, 51, 1531-1534.	2.9	7
33	Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma. , 2021, 9, e002754.		7
34	MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 515-520.	5.2	5
35	Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. <i>EJNMMI Research</i> , 2022, 12, 4.	2.5	4
36	Concomitantly discovered visceral artery aneurysms do rarely grow during cancer therapy. <i>Clinical Anatomy</i> , 2022, 35, 296-304.	2.7	3

#	ARTICLE	IF	CITATIONS
37	Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 1371.	3.7	3
38	Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103197.	1.0	2
39	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 148, 331.	2.5	2
40	Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8521-8521.	1.6	2
41	Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT). <i>Blood</i> , 2018, 132, 1979-1979.	1.4	1
42	Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8001-8001.	1.6	1
43	CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2900-2900.	1.4	1
44	RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade. <i>Blood</i> , 2019, 134, 624-624.	1.4	1
45	Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers. <i>Blood</i> , 2021, 138, 1257-1257.	1.4	1
46	IFN-Gamma Producing Regulatory T Cells Counterbalance T Cell-Mediated Injury to the Intestinal Stem Cell Compartment in Mice and Humans. <i>Blood</i> , 2021, 138, 89-89.	1.4	1
47	Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution. <i>Blood</i> , 2021, 138, 3278-3278.	1.4	1
48	Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. <i>Annals of Hematology</i> , 2022, 101, 1311-1319.	1.8	1
49	ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations. <i>EJHaem</i> , 2021, 2, 280-284.	1.0	0
50	Multisite Phosphorylation of NIPA at G2/M.. <i>Blood</i> , 2007, 110, 3348-3348.	1.4	0
51	NIPA Phosphorylation and Inactivation at G2/M Is Mediated by ERK2.. <i>Blood</i> , 2009, 114, 2513-2513.	1.4	0
52	Cereblon and Redox in Plasma Cells. <i>Blood</i> , 2017, 130, SCI-9-SCI-9.	1.4	0
53	Type I Interferon Signaling before Hematopoietic Stem Cell Transplantation Lowers Donor T Cell Activation Via Reduced Allogenicity of Recipient Cells. <i>Blood</i> , 2019, 134, 4431-4431.	1.4	0
54	Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group. <i>Blood</i> , 2019, 134, 1840-1840.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Microbial-Derived Metabolites Induce Epithelial Recovery Via the Sting Pathway in Mice and Men and Protect from Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 87-87.	1.4	0